A Prospective, Open-label TElmisartan/AMlodipine Single Pill STudy to Assess the Efficacy in Patients With Essential Hypertension who are not controlled on RAASi mono-therapy being switched.

Trial Profile

A Prospective, Open-label TElmisartan/AMlodipine Single Pill STudy to Assess the Efficacy in Patients With Essential Hypertension who are not controlled on RAASi mono-therapy being switched.

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Dec 2013

At a glance

  • Drugs Amlodipine/telmisartan (Primary)
  • Indications Essential hypertension
  • Focus Registrational; Therapeutic Use
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 31 May 2012 Planned number of patients changed from 502 to 650 as reported by European Clinical Trials Database record.
    • 28 Jun 2011 Actual end date (1 May 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top